Get the Stockscreener App
82.39
0.22%
-0.005
Edwards Lifesciences Corp stock is traded at $82.39, with a volume of 1.84M.
It is down -0.22% in the last 24 hours and up +1.51% over the past month.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$82.39
Open:
$82.29
24h Volume:
1.84M
Relative Volume:
0.38
Market Cap:
$47.43B
Revenue:
$6.30B
Net Income/Loss:
$1.07B
P/E Ratio:
44.76
EPS:
1.8406
Net Cash Flow:
$1.09B
1W Performance:
+3.11%
1M Performance:
+1.51%
6M Performance:
-4.43%
1Y Performance:
+5.34%
1-Day Range:
$80.87
$82.61
1-Week Range:
$78.29
$82.88
52-Week Range:
$72.30
$87.89
Edwards Lifesciences Corp Stock (EW) Company Profile
Name
Edwards Lifesciences Corp
Sector
Industry
Phone
(949) 250-2500
Address
ONE EDWARDS WAY, IRVINE, CA
Compare EW vs ABT, SYK, MDT, BSX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EW
Edwards Lifesciences Corp
|
82.38 | 47.44B | 6.30B | 1.07B | 1.09B | 1.8406 |
ABT
Abbott Laboratories
|
88.63 | 153.12B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
318.27 | 120.08B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
78.37 | 99.27B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
56.70 | 83.12B | 20.62B | 3.56B | 3.48B | 2.3847 |
Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-01-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-26 | Upgrade | TD Cowen | Hold → Buy |
| Dec-18-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-03-25 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-29-25 | Upgrade | Jefferies | Hold → Buy |
| Oct-29-25 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-29-25 | Upgrade | BTIG Research | Neutral → Buy |
| Apr-24-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-30-25 | Upgrade | Stifel | Hold → Buy |
| Jan-16-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-11-24 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jul-31-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jul-29-24 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jul-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-25-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-25-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-25-24 | Downgrade | TD Cowen | Buy → Hold |
| Jul-25-24 | Downgrade | Truist | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| May-22-24 | Upgrade | Citigroup | Neutral → Buy |
| May-14-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Mar-07-24 | Upgrade | BofA Securities | Neutral → Buy |
| Feb-02-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-11-23 | Downgrade | Citigroup | Buy → Neutral |
| Nov-28-23 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-26-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-08-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-06-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-31-23 | Downgrade | Bernstein | Outperform → Underperform |
| Jan-30-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-06-22 | Downgrade | Stifel | Buy → Hold |
| Oct-28-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-26-22 | Initiated | Mizuho | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-29-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Mar-16-22 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-27-22 | Reiterated | Citigroup | Buy |
| Jan-27-22 | Reiterated | Evercore ISI | Outperform |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | Stifel | Buy |
| Jan-27-22 | Reiterated | UBS | Neutral |
| Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Dec-06-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-30-21 | Reiterated | Canaccord Genuity | Buy |
| Jul-30-21 | Reiterated | Deutsche Bank | Hold |
| Jul-30-21 | Reiterated | Jefferies | Buy |
| Jul-30-21 | Reiterated | Morgan Stanley | Overweight |
| Jul-30-21 | Reiterated | Oppenheimer | Outperform |
| Jul-30-21 | Reiterated | Stifel | Buy |
| Jul-30-21 | Reiterated | UBS | Neutral |
| Jul-30-21 | Reiterated | Wells Fargo | Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Apr-05-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-11-20 | Reiterated | Canaccord Genuity | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Underperform |
| Apr-28-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Outperform |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-24-19 | Reiterated | Canaccord Genuity | Buy |
| Sep-23-19 | Initiated | Piper Jaffray | Overweight |
| Jul-24-19 | Reiterated | BofA/Merrill | Buy |
| Mar-18-19 | Reiterated | Canaccord Genuity | Buy |
| Jan-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jan-03-19 | Initiated | Deutsche Bank | Hold |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-16-18 | Initiated | Barclays | Underweight |
| Oct-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Oct-02-18 | Downgrade | Guggenheim | Buy → Neutral |
View All
Edwards Lifesciences Corp Stock (EW) Latest News
Handelsbanken Fonder AB Has $102.60 Million Stock Position in Edwards Lifesciences Corporation $EW - MarketBeat
Insider Sell Alert: Daniel Lippis Sells Shares of Edwards Lifesc - GuruFocus
Edwards Lifesciences (NYSE:EW) VP Sells $50,306.80 in Stock - MarketBeat
Edwards Lifesciences CVP Lippis sells $50,306 of common stock By Investing.com - Investing.com Australia
Edwards Lifesciences CVP Lippis sells $50,306 of common stock - Investing.com
Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M - TradingView
Edwards Lifesciences exec sells 620 shares after option exercise | EW Insider Trading - Stock Titan
Edwards Lifesciences (EW) CVP Donald Bobo Jr. sells 17,968 shares in open-market trades - Stock Titan
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Edwards Lifesciences (NYSE: EW) Form 144 lists 150,758 units via broker - Stock Titan
[144] Edwards Lifesciences Corp SEC Filing - Stock Titan
Top Edwards Lifesciences (EW) Competitors 2026 - MarketBeat
Are Wall Street Analysts Bullish on Edwards Lifesciences Stock? - Barchart.com
Scaling heart valve manufacturing to deliver life-saving treatments across Europe - Jacobs
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch
VIRGINIA RETIREMENT SYSTEMS ET Al Trims Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences' (NYSE:EW) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
[Form 4] Edwards Lifesciences Corp Insider Trading Activity - Stock Titan
Edwards Lifesciences CEO Zovighian sells $2.83m in shares By Investing.com - Investing.com Nigeria
Edwards Lifesciences CEO Zovighian sells $2.83m in shares - Investing.com
Edwards Lifesciences (EW) CVP exercises 13,457 performance shares with 7,469 withheld for taxes - Stock Titan
Edwards Lifesciences (EW) executive vests performance units and withholds shares for taxes - Stock Titan
Edwards Lifesciences (NYSE: EW) lists vested RSUs and prior 22,430-share sale - Stock Titan
EW Technical Analysis | Trend, Signals & Chart Patterns | EDWARDS LIFESCIENCES CORP (NYSE:EW) - ChartMill
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock By Investing.com - Investing.com Nigeria
Edwards Lifesciences CVP Wayne Markowitz sells $47,279 in stock - Investing.com UK
Edwards Lifesciences (NYSE: EW) CFO exercises performance units, withholds 11,004 shares for taxes - Stock Titan
Edwards Lifesciences (EW) CEO awarded stock, options and makes share gifts - Stock Titan
Edwards Lifesciences (NYSE: EW) executive logs routine tax-withholding share disposition - Stock Titan
Is Edwards Lifesciences Corp (EW) a Bargain After 3.5% Drop? GF Value Says Undervalued - GuruFocus
Edwards Lifesciences Corp. stock underperforms Monday when compared to competitors - MarketWatch
Edwards Lifesciences (EW) is Benefitting from Expanding Its Aortic Valve Franchise - Yahoo Finance
Nwam LLC Grows Position in Edwards Lifesciences Corporation $EW - MarketBeat
EW SEC FilingsEdwards Lifesciences Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Generali Asset Management SPA SGR Has $6.18 Million Stake in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (EW) CVP awarded stock, options and performance rights - Stock Titan
Edwards Lifesciences Corp (EW) Shares Fall 3.4% -- What GF Score of 97 Tells Investors - GuruFocus
Edwards Lifesciences Corp. stock underperforms Friday when compared to competitors - MarketWatch
Edwards Lifesciences (NYSE: EW) investors approve equity and pay measures - Stock Titan
Swedbank AB Sells 192,442 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Principal Financial Group Inc. Grows Stock Holdings in Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) director granted new stock awards - Stock Titan
QRG Capital Management Inc. Acquires 18,172 Shares of Edwards Lifesciences Corporation $EW - MarketBeat
Edwards Lifesciences (NYSE: EW) lifts Q1 2026 sales on TAVR and TMTT growth - Stock Titan
Insider Sell: Daniel Lippis Sells Shares of Edwards Lifesciences Corp (EW) - GuruFocus
Edwards Lifesciences Appoints Theodora Mistras as Chief Financial Officer Effective May 2026 - Minichart
symbol__ Stock Quote Price and Forecast - CNN
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock - Investing.com UK
Edwards Lifesciences CVP, TAVR, sells $170,160 in stock By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) CVP Lippis sells 2,038 shares after option exercises - Stock Titan
Edwards Lifesciences (EW) executive logs 282-share tax withholding on Form 4 - Stock Titan
Edwards Lifesciences Corp Stock (EW) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
2.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):